Close Menu

Maybe there is something to Affinium Pharmaceuticals’ new name. Last week the Toronto-based company, formerly known as Integrative Proteomics, announced that it had struck a deal valued at $30 million with Pfizer to comprehensively study and develop leads for an unspecified number of the big pharma’s target proteins. And on Monday of last week, the Cystic Fibrosis Foundation agreed to give Affinium and the Hospital for Sick Children in Toronto $5 million to identify potential drug targets for that disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers have developed a robotic lab assistant, the Verge reports.

CBC News reports Canada's Supreme Court is to rule on the constitutionality of the country's genetic non-discrimination law today.

The Associated Press reports the World Health Organization is sending experts to China to investigate the animal source of SARS-CoV-2.

In Science this week: atlas of affected cell populations in idiopathic pulmonary fibrosis, and more.